Loading
Rank hospitals and companies each year on how well their trial participants match the people with the disease in their area, and use the ranking when deciding who gets public research money and trial contracts.
An independent body computes, for each site and sponsor, participation-to-prevalence ratios by race, ethnicity, age, sex and rurality across their oncology trials, publishes the index annually, and public funders and cooperative groups weight site selection and grant scoring by it. Sponsors use it in site selection.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, National Cancer Institute (NIH).
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.